Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat

No abstract is available for this paper.

• Publication year

  2015

• Venue

  AAPS Journal

• Publication date

  2015-04-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1208/s12248-015-9771-3PMID 25924888PMCID PMC4477001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative cumulative biodistribution of antibodies in mice

  2014cited by this paper
• Investigation of the Influence of Nephropathy on Monoclonal Antibody Disposition: A Pharmacokinetic Study in a Mouse Model of Diabetic Nephropathy

  2014cited by this paper
• Contribution of Renal and Non‐Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease

  2013cited by this paper
• Increased lysosomal proteolysis counteracts protein accumulation in the proximal tubule during focal segmental glomerulosclerosis.

  2013cited by this paper
• How biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes

  2013cited by this paper
• Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

  2013cited by this paper
• Diabetic nephropathy: diagnosis, prevention and treatment

  2013cited by this paper
• Significance of Urinary Full-Length and Ectodomain Forms of Megalin in Patients With Type 2 Diabetes

  2012cited by this paper
• Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications

  2012cited by this paper
• Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs

  2012cited by this paper
• Endocytic receptors in the renal proximal tubule.

  2012cited by this paper
• Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial

  2012cited by this paper
• Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice

  2012cited by this paper
• Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

  2012cited by this paper
• Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration

  2012cited by this paper
• Association Between Urinary IgG and Relative Risk for Factors Affecting Proteinuria in Type 2 Diabetic Patients

  2012cited by this paper
• Megalin/cubilin-mediated uptake of FITC-labeled IgG by OK kidney epithelial cells.

  2011cited by this paper
• Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.

  2011cited by this paper
• The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults.

  2011cited by this paper
• Models of chronic kidney disease.

  2010cited by this paper
• Potential role of ustekinumab in the treatment of chronic plaque psoriasis

  2010cited by this paper
• Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis

  2010cited by this paper
• Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

  2010cited by this paper
• Potential role of ustekinumab in the treatment of chronic plaque psoriasis

  2010cited by this paper
• Metabolic disturbances linked to obesity: the role of impaired tissue perfusion.

  2009cited by this paper
• Non enzymatic glycosylation of IgG and their urinary excretion in patients with diabetic nephropathy

  2009cited by this paper
• A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.

  2007cited by this paper
• NF- B Signaling Regulates Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG via Intronic Binding Sequences

  2007cited by this paper
• Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

  2007cited by this paper
• Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension.

  2007cited by this paper
• NF-κB Signaling Regulates Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG via Intronic Binding Sequences1

  2007cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• FcRn mediates elongated serum half-life of human IgG in cattle.

  2006cited by this paper
• Hypercatabolism of IgG in mice with lupus-like syndrome

  2005cited by this paper
• Hypertension‐Independent Microvascular Rarefaction in the Obese Zucker Rat Model of the Metabolic Syndrome

  2005cited by this paper
• Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy.

  2004cited by this paper
• [Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of out patients with type 2 diabetes mellitus].

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Prevalência de complicações micro e macrovasculares e de seus fatores de risco em pacientes com diabetes melito do tipo 2 em atendimento ambulatorial

  2004cited by this paper
• Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).

  2003cited by this paper
• Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats.

  2003cited by this paper
• Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy.

  2002cited by this paper
• Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.

  2001cited by this paper
• A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat.

  2001cited by this paper
• Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus.

  2000cited by this paper
• Nephropathy in patients with type 2 diabetes mellitus.

  1999cited by this paper
• Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice.

  1998cited by this paper
• Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity.

  1996cited by this paper
• Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats.

  1996cited by this paper
• Advanced protein glycosylation in diabetes and aging.

  1995cited by this paper
• Glycation increases the vascular clearance rate of IgG in mice

  1993cited by this paper
• Subcutaneous erythropoietin therapy: comparison of three different sites of injection.

  1991cited by this paper
• Impairment by glycation of immunoglobulin G Fc fragment function.

  1990cited by this paper
• Human IgG subclass measurements in the clinical laboratory.

  1987cited by this paper
• High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules.

  1985cited by this paper
• Nonenzymatic glycation of immunoglobulins leads to an impairment of immunoreactivity.

  1985cited by this paper
• A THEORETICAL MODEL OF GAMMA-GLOBULIN CATABOLISM.

  1964cited by this paper

• Helminth-derived antigens induce an immunomodulatory response in autoimmune type 1 diabetes mellitus by promoting regulatory immune responses

  2025cites this paper
• Super-Resolution Ultrasound Imaging of Renal Vascular Alterations in Zucker Diabetic Fatty Rats during the Development of Diabetic Kidney Disease

  2023cites this paper
• Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy

  2023cites this paper
• GP73 blockade alleviates abnormal glucose homeostasis in diabetic mice.

  2022cites this paper
• Immunoglobulin G Is a Novel Substrate for the Endocytic Protein Megalin

  2021cites this paper
• Preventive Role of Salsalate in Diabetes Is Associated With Reducing Intestinal Inflammation Through Improvement of Gut Dysbiosis in ZDF Rats

  2020cites this paper
• Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms

  2020cites this paper
• Understanding Inter-Individual Variability in Monoclonal Antibody Disposition

  2019cites this paper
• Preparation of a nanoscale dihydromyricetin-phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations.

  2019cites this paper
• Increased megalin expression in early type 2 diabetes: role of insulin-signaling pathways.

  2018cites this paper
• Combination and haplotype effects of protein tyrosine phosphatase receptor type D gene polymorphisms on type 2 diabetes in a sample of Iranian population: A pilot study

  2018cites this paper
• Expression and Activity of CYP2C8 and 2C9 in Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

  2018cites this paper
• The ZDSD rat: a novel model of diabetic nephropathy.

  2017cites this paper
• Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy

  2016cites this paper
• An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats

  2015cites this paper
• World Journal of Diabetes

  year unknowncites this paper